Novasenta is focused on the discovery of novel therapeutic targets to develop innovative and effective treatments for cancer patients. The company has developed a proprietary platform for single-cell RNA based analysis of high-quality, human tumor samples and combined it with its advanced data mining and target validation abilities to accelerate the path from discovery to drug development. The company’s pipeline includes three programs representing the next generation of immuno-oncology targets and drug candidates.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Platform for single-cell RNA based analysis of high-quality, human tumor samples, combined with ML
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Seeking partnerships for platform for discovery and validation of novel targets
Speaker
